Kelly M. Mcmasters, MD, PhD | Authors

An Argument for Aggressive Resection in Melanoma

October 15, 2013

Any minimization of therapy in the name of reducing morbidity requires careful consideration. Reducing morbidity in melanoma is certainly a laudable goal, but locoregional disease control and cure must remain our primary objectives.

Extending the Role of Hepatic Metastasectomy in Stage IV Melanoma and Breast Cancer: Patient Selection is Critical

November 15, 2011

Resection of liver metastases represents a major advance of the last few decades in the treatment of colorectal cancer.

Current Status of Sentinel Node Surgery in Breast Cancer

December 01, 2003

Krag and Harlow believe thatsentinel lymph node biopsyfor breast cancer is still an experimentalprocedure because “longtermrandomized trials comparing thesurvival outcome of this procedurewith that of conventional axillary noderesection have not been completed.”Specifically, they are awaiting the resultsof the American College of SurgeonsOncology Group (ACOSOG)Z0011 trial and the National SurgicalAdjuvant Breast and Bowel Project(NSABP) B-32 trial before they makea determination about the “safety” ofthis procedure.[1] This is a commonmisconception, because these studieswill not prove whether sentinel nodebiopsy results in equivalent survivalcompared to standard level I/II axillarydissection in patients with clinicallynode-negative breast cancer. Thetime has come for clear thinking aboutthe design of these trials and precisereasoning about the interpretation oftheir ultimate results.